IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to 'listen for the sounds of IPF'

Boehringer IngelheimIPF is a progressive and debilitating disease which causes continual and irreversible damage to the lungs.(1) Early diagnosis is vital because without appropriate medical intervention, the opportunity to slow disease progression is lost. However, diagnosis can be challenging.(1,2) This year for IPF World Week (16 - 24 September), Boehringer Ingelheim is raising awareness of 'the sounds of IPF' helping physicians recognise the velcro-like crackle which can be heard in the lungs of the majority of IPF patients on auscultation.(2) The goal is earlier accurate medical diagnosis which should lead to immediate initiation of treatment.

Though it is a rare disease, IPF affects approximately three million people worldwide and has a devastating impact on patient lives.(3) Professor Toby Maher, Royal Brompton Hospital commented: "IPF is a disease with an unpredictable course where exacerbations can occur at any time without warning. Clinical trials have shown us that patients without treatment lose lung function even when their disease is in the earliest stages. Antifibrotic treatment can reduce this decline by approximately 50%. Therefore any delay in initiating treatment puts patients at risk of irreversible loss of lung capacity." There are two approved antifibrotic drugs shown to slow the disease progression in IPF that are recommended by international guidelines.(4)

Analysis of results from two global surveys sponsored by Boehringer Ingelheim involving over 400 pulmonologists and 150 patients show that patients and physicians agree that maintaining lung function for as long as possible is one of the key treatment priorities. Despite this alignment in priorities and the availability of medicines for use in IPF patients, around one in three patients (30%) do not feel involved in treatment discussions at all.(5)

Liam Galvin, Secretary of the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation (EU-IPFF), explained: "What I hear loud and clear from patients is that a key concern for them is getting a confirmed diagnosis. Next is talking with their physician about treatment that can slow the progression of IPF. The realisation that you have IPF is shattering, and patients have to think about their future: they worry about lung function decline and they fear acute exacerbations."

To raise awareness of the importance of 'listening to the sounds of IPF', Boehringer Ingelheim has created a range of educational tools. Physicians interested in learning more can visit the online resource inIPF.com. In addition, LifewithIPF.com is a platform for patients where a range of background materials, IPF patient video stories and webinars with pulmonologists can be found.

"Time is of essence. If patients can be diagnosed timely and referred to an expert pulmonologist to initiate treatment at the earliest opportunity, we stand a greater chance of making a real difference in the ongoing challenge of managing this devastating disease. We need to raise awareness for IPF and act together to help patients and their families," said Ivan Blanarik, Senior Vice President and Head of Therapeutic Area Respiratory, Boehringer Ingelheim.

Boehringer Ingelheim in fibrosing lung conditions
Improving the wellbeing of people with fibrosing lung diseases such as IPF is a priority for Boehringer Ingelheim. As part of this commitment, Boehringer Ingelheim is currently enrolling patients to participate in further clinical trials investigating the efficacy of nintedanib in treating interstitial lung disease associated with conditions other than IPF, including people with systemic sclerosis who have also developed interstitial lung disease (SSc-ILD) and people with other progressive fibrosing interstitial lung diseases (PF-ILD).*

About Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

* Nintedanib is currently not approved for use in SSc-ILD or PF-ILD and its safety and efficacy has not yet been established

1. Ley B, et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-40.
2. Cottin V, et al. Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2012;40:519-521.
3. Nalysnyk L., et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21(126):355-361.
4. Raghu G, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis: Executive Summary. Am J Respir Crit Care Med. 2015; 192(2)238 - 248.
5. Data on file. Boehringer Ingelheim.

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...